The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hepatocellular carcinoma (HCC) and bone metastases (Mets).
 
James J. Harding
Consulting or Advisory Role - MedImmune
Research Funding - Calithera Biosciences (Inst); Lilly (Inst); Polaris (Inst)
 
Ghaith Abu Zeinah
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Dwight Hall Owen
No Relationships to Disclose
 
Michele Ly
No Relationships to Disclose
 
Maeve Aine Lowery
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)
 
Marinela Capanu
No Relationships to Disclose
 
Leonard Saltz
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer; Boehringer Ingelheim; Lilly; pfizer; Roche/Genentech; Sun Pharma
Research Funding - Taiho Pharmaceutical
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Astellas Pharma; AstraZeneca (I); Celgene; Celsion; cipla; Exelixis; IntegraGen; Jennerex; Lilly/ImClone; MedImmune; Novartis; Pharmacyclics (I); Sanofi (I); Silenseed (I); Vicus Therapeutics
Research Funding - Abbott Laboratories (Inst); Amgen (Inst); Bayer (Inst); Exelixis (Inst); Genentech (Inst); Lilly/ImClone (Inst); Novartis (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris